newsfilter
← Latest News
GlobeNewswire·

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027